AAAAAA

   
Results: 1-10 |
Results: 10
THE ROLE OF ACE-INHIBITORS IN THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS - A CLINICAL APPROACH - INTRODUCTION
Authors: OSTERGREN J
Citation: J. Ostergren, THE ROLE OF ACE-INHIBITORS IN THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS - A CLINICAL APPROACH - INTRODUCTION, International journal of clinical practice, 1998, pp. 2-2
SKIN MICROVASCULAR DILATATION RESPONSE TO ACETYLCHOLINE AND SODIUM-NITROPRUSSIDE IN PERIPHERAL ARTERIAL-DISEASE
Authors: JAGREN C GAZELIUS B IHRMANSANDAL C LINDBLAD LE OSTERGREN J
Citation: C. Jagren et al., SKIN MICROVASCULAR DILATATION RESPONSE TO ACETYLCHOLINE AND SODIUM-NITROPRUSSIDE IN PERIPHERAL ARTERIAL-DISEASE, Journal of vascular research, 35(4), 1998, pp. 295-295
TRANSCUTANEOUS OXYGEN-TENSION AND TOE PRESSURE AS PREDICTORS FOR OUTCOME OF DIABETIC FOOT ULCERS
Authors: KALANI M BRISMAR K FAGRELL B OSTERGREN J JORNESKOG G
Citation: M. Kalani et al., TRANSCUTANEOUS OXYGEN-TENSION AND TOE PRESSURE AS PREDICTORS FOR OUTCOME OF DIABETIC FOOT ULCERS, Journal of vascular research, 35(4), 1998, pp. 296-296
TRANSCUTANEOUS OXYGEN-TENSION AND TOE PRESSURE AS IMPAIRMENT OF CEREBRAL BLOOD-FLOW IN PATIENTS WITH PREDICTORS FOR OUTCOME OF DIABETIC FOOT ULCERS
Authors: KALANI M BRISMAR K FAGRELL B OSTERGREN J JORNESKOG G
Citation: M. Kalani et al., TRANSCUTANEOUS OXYGEN-TENSION AND TOE PRESSURE AS IMPAIRMENT OF CEREBRAL BLOOD-FLOW IN PATIENTS WITH PREDICTORS FOR OUTCOME OF DIABETIC FOOT ULCERS, Journal of vascular research, 35, 1998, pp. 9-9
EFFECT OF AMLODIPINE VERSUS FELODIPINE EXTENDED-RELEASE ON 24-HOUR AMBULATORY BLOOD-PRESSURE IN HYPERTENSION
Authors: OSTERGREN J ISAKSSON H BRODIN U SCHWAN A OHMAN KP
Citation: J. Ostergren et al., EFFECT OF AMLODIPINE VERSUS FELODIPINE EXTENDED-RELEASE ON 24-HOUR AMBULATORY BLOOD-PRESSURE IN HYPERTENSION, American journal of hypertension, 11(6), 1998, pp. 690-696
ADRENALINE RESPONSIVENESS IN MILD HYPERTENSION - NO EVIDENCE FOR ALTERED BETA-ADRENOCEPTOR SENSITIVITY
Authors: KAHAN T HJEMDAHL P LINDVALL K OSTERGREN J DEFAIRE U
Citation: T. Kahan et al., ADRENALINE RESPONSIVENESS IN MILD HYPERTENSION - NO EVIDENCE FOR ALTERED BETA-ADRENOCEPTOR SENSITIVITY, Journal of cardiovascular pharmacology, 32(5), 1998, pp. 753-759
MAIN RESULTS OF THE LOSARTAN VERSUS AMLODIPINE (LOA) STUDY ON DRUG TOLERABILITY AND PSYCHOLOGICAL GENERAL WELL-BEING
Authors: DAHLOF B LINDHOLM LH CARNEY S PENTIKAINEN PJ OSTERGREN J
Citation: B. Dahlof et al., MAIN RESULTS OF THE LOSARTAN VERSUS AMLODIPINE (LOA) STUDY ON DRUG TOLERABILITY AND PSYCHOLOGICAL GENERAL WELL-BEING, Journal of hypertension, 15(11), 1997, pp. 1327-1335
TRANSCUTANEOUS OXYGEN-TENSION AND TOE PRESSURE AS PREDICTORS FOR OUTCOME OF DIABETIC FOOT ULCERS
Authors: KALANI M BRISMAR K FAGRELL B OSTERGREN J JORNESKOG G
Citation: M. Kalani et al., TRANSCUTANEOUS OXYGEN-TENSION AND TOE PRESSURE AS PREDICTORS FOR OUTCOME OF DIABETIC FOOT ULCERS, Diabetologia, 40, 1997, pp. 1898-1898
PROGNOSIS IN THERAPY-RESISTANT HYPERTENSION
Authors: ISAKSSON H OSTERGREN J
Citation: H. Isaksson et J. Ostergren, PROGNOSIS IN THERAPY-RESISTANT HYPERTENSION, Journal of internal medicine, 236(6), 1994, pp. 643-649
EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL LITER (200 TO 300 MG DL) PLUS 2 ADDITIONAL ATHEROSCLEROTIC RISK-FACTORS
Authors: BEHOUNEK BD MARKOWITZ JS BERGMAN M MCGOVERN ME KASSLERTAUB KB VANHANEN H ELORANTA M JUVONEN J KANTOLA I KEKKI S KIVELA H KNUTAR F NISSEN M SALMI J SALONEN R TARPILA S TUNTURIHIHNALA H AMANN FW BERENDES G BONNER G DUBACH UC EGGSTEIN M FRANKENBERG HV FROER KL HOHL H HOPPE F KUMMER H MARZ W MOCCETTI T NOSEDA G REUTTER FW SCHWENKE R VOSSCHULTE G WAMBACH G WEIDMANN P BONNIER JJRM DEWEERD P HUIGE MC JANSEN LJ TERIJDT AJ TEVELDE K OLSSON AG LARSSON H ASPLUND J DAHLQVIST A LONNQVIST F FRITHZ G HOGLUND C KJELLSTROM T KUYLENSTIERNA J MOLLER B OSTERGREN J CRAMB R DAVIES J",IVERSON,"JOHNSTON GD MUNRO A PEACOCK I RITCHIE LD RITTER J RYLANCE PB SEVER PS SIMMONS RL
Citation: Bd. Behounek et al., EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL LITER (200 TO 300 MG DL) PLUS 2 ADDITIONAL ATHEROSCLEROTIC RISK-FACTORS, The American journal of cardiology, 72(14), 1993, pp. 1031-1037
Risultati: 1-10 |